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OBJECTIVE: To compare health-related quality of life
(HRQoL) among relapsing-remitting multiple sclerosis (RRMS)
patients receiving long-term glatiramer acetate (GA) treatment
with those having similar disease duration but remaining
untreated or treated short-term with GA or beta-interferons.
METHODS: Patients followed in year nine of the prospective,
open-label continuation of the US pivotal study of GA were
consented for this cross-sectional survey [GA Group] at ofﬁce
visits. MS Surveys were presented for home completion and
mail-back. Concurrent RRMS comparators from the North
American Research Committee on MS registry were selected by
matching 4:1 (untreated) and 1:1 (per treatment) on gender,
education level, present age +2 years, and duration of MS
(years). Returned postcards afﬁrming participation prompted
mailed MS Surveys. Each survey included the validated MS
Quality of Life Inventory (MSQLI), and Goodin’s MS Ques-
tionnaire (disability), satisfaction with life, health, therapy, and
sociodemographic characteristics. Matched paired comparisons
used Hotelling multivariate T-square analysis and McNemar’s
test. RESULTS: Response rates were 94.8% for GA Group and
78.4% for comparators. The GA Group reported signiﬁcantly
more life satisfaction (Mean [M]: 2.20 vs. 3.03; 95%CI = 0.03,
1.45) and better health on the Mental Component Summary
score (M: 49.55 vs. 44.59; 95%CI = -10.43, -0.09) of the
SF-36 in the MSQLI than matched untreated comparators.
Relative to matched comparators treated with short-term GA
or beta-interferons, the GA Group had signiﬁcantly lower mean
disability scores and better health on the Physical Component
Summary score of the SF-36 and they reported greater satisfac-
tion with therapy. CONCLUSION: This comparative study of
HRQOL suggests that patients with RRMS who have been
treated with GA long-term have realized more life satisfaction
and better mental health than those with a similar disease dura-
tion who remain untreated, and their physical function may be
better than those who have been treated short-term with GA or
beta-interferons.
PND34
ASSOCIATION BETWEEN CHANGE IN OVERALL QUALITY OF
LIFE (QOL), DISEASE LEVEL AND FUNCTIONAL STATUS
SINCE NATALIZUMAB INITIATION
Rajagopalan K1, Stephenson JJ2, Kamat S3
1Biogen Idec Pharmaceuticals, Cambridge, MA, USA, 2HealthCore Inc,
Wilmington, DE, USA, 3HealthCore,Wilmington, DE, USA
OBJECTIVE: To assess the relationship between changes in
patient-reported QoL, disease level and functional status after
three months on natalizumab (TYSABRI). METHODS: MS
patients who received their 3rd natalizumab infusion and were
enrolled in the manufacturer’s restricted distribution program
(TOUCH), participated in a 20-minute cross-sectional internet or
telephone survey. Outcome measures included overall quality of
life (QoL) change since initiating natalizumab using a 3-point
scale (1—worse, 2—no change, 3—better), and pre/post disease
level and functional status change. Disease level was measured on
a 7 point scale: 0—“normal with no limitations on activity”
through 6—“wheelchair bound” whereas functional status was
measured on a 5 point scale: 1—“able to carry out usual daily
activities” through 5—“required assistance”. Paired and inde-
pendent sample t-tests were used based on the outcome metric.
RESULTS: Results from 319 patients in this ongoing survey
(expected n  400) indicated that 75% were female. Overall
QoL improved among 47% of patients, even in the short time on
natalizumab. Only 3% of patients reported a worsening in QoL.
On average, these patients were diagnosed with MS 15 years ago
compared with the sample mean of 11 years. Increases in mean
disease level change scores (0.30  1.13, p < 0.001) and func-
tional status change scores (0.36  0.80, p < 0.001) were
reported, indicating signiﬁcant improvements. Compared to
patients reporting no change or worsening QoL, patients report-
ing improved QoL had signiﬁcantly higher mean disease change
scores (0.56  1.28 vs. 0.08  0.92, p < 0.001) and functional
status change scores (0.71  0.82 vs. 0.04  0.63, p < 0.001).
CONCLUSION: After three months on natalizumab, patients
reported improvements in overall QoL, disease level and func-
tional status. These outcomes were positively and signiﬁcantly
associated with one another suggesting that, in a real world
setting, patients may begin experiencing improvements in disease
progression and QoL as early as three months after natalizumab
initiation.
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OBJECTIVE: To assess multiple sclerosis (MS) patient-reported
experiences with natalizumab (TYSABRI) in a real-world setting.
METHODS: MS patients who received their 3rd natalizumab
infusion and were enrolled in the manufacturer’s restricted dis-
tribution program (TOUCH), participated in a 20-minute cross-
sectional internet or telephone survey. Patient-reported measures
included an adapted version of the Multiple Sclerosis Impact
Scale-29 (MSIS-29), pre/post disease level and functional status
scores and prior MS drug use. MSIS-29 responses were modiﬁed
to measure patient-perceived change since initiating natalizumab.
Paired t-tests assessed pre/post changes in disease level and func-
tional status, where positive change indicated improvement.
RESULTS: Results from 319 patients in this ongoing survey
(expected n  400) indicated that 75% were female and, on
average, were diagnosed with MS over 11 years ago. Almost all
(97%) patients used 1 MS drug before natalizumab. The most
frequently used drugs were: interferon beta-1a (Avonex) (67%),
glatiramer acetate (Copaxone) (49%), interferon beta-1b (Beta-
seron) (36%) and interferon beta-1a (Rebif) (35%). Despite the
short treatment duration, there were signiﬁcant improvements in
disease level (0.30  1.13; t = 4.78; p < 0.001) and functional
status (0.36  0.80; t = 7.96; p < 0.001). MSIS-29 items with
greatest reported improvement since initiating natalizumab were:
“worries related to MS” (66%), “feeling unwell” (64%), ability
to do “physically demanding tasks” (63%), “problems with
balance” (61%), “feeling mentally fatigued” (61%) and “difﬁ-
culties moving about indoors” (60%). Items with least reported
improvement were: “tremors of your arms or legs” (49%),
“being stuck at home” (49%), “problems sleeping” (49%) and
“problems using transport” (42%). On average, patients
reported improvement on 13 of 29 (45%) MSIS-29 items. CON-
CLUSION: After only 3 months on natalizumab, patients
reported improvements on MSIS-29 items, disease level and func-
tional status. While preliminary, these early results are suggestive
of natalizumab’s beneﬁcial effect on patients and warrant further
long term investigation of its impact on patient outcomes in a
real-world setting.
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